1) Infliximab 바이오시밀러 : Inflectra MS와 처방수량 전월 대비 증가.

- Inflectra(셀트리온/Pfizer) : 88.1천 Unit(+8.1% MoM), MS 14.2%(+1.7%p).

- Renflexis(삼성바이오/MSD) : 41.5천 Unit(-1.3% MoM), MS 6.7%(+0.3%p)

2) Rituximab 바이오시밀러 : Ruxience - Truxima MS 격차 확대

- Truxima(셀트리온/TEVA) : 888.9천 Unit(+4.3% MoM), MS 21.3%(+0.7%p) .

- Ruxience(Pfizer) : 1,004.6천 Unit(+4.9% MoM), MS 24.1%(+0.9%p).

3) Trastuzumab 바이오시밀러 : MS 소폭 상승.

- Kanjinti(Amgen/Abbvie) : 1,053.6천 Unit(+2.4% MoM), MS 42.6%(-0.1%p).

- Ogivri(Mylan/Biogen) : 218.8천 Unit(+9.4% MoM), MS 8.8%(+0.5%p).

- Others(Trazimera+Herzuma) : 226.3천 Unit(+3.9% MoM), MS 9.1%(+0.1%p).

4) Bevacizumab 바이오시밀러 : MS Zirabev 상승, Mvasi 하락.

- Mvasi(Amgen/Abbvie) : 1,940.1 천 Unit(+2.6 % MoM), MS 48.4%(-0.4 %p).

- Zirabev(Pfizer) : 466.2천 Unit(+9.3% MoM), MS 11.6%(+0.6%p).

<자료제공:메리츠증권>

김사랑 기자  kimsarang0420

<저작권자 © 팜스탁, 무단 전재 및 재배포 금지>